ArticleJournal of visualized experiments : JoVE2017
Automated Contraction Analysis of Human Engineered Heart Tissue for Cardiac Drug Safety Screening.
Article in Journal of visualized experiments : JoVE, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Investigating the Anticancer Effects of Sulforaphane in an In Vitro Coculture Model of Prostate Cancer Cells with Engineered Heart Tissue.ACS pharmacology & translational science · 2025Article
- Integrating Bioprinting and Increased Throughput: Next-Generation Models for Cardiac Research.International journal of molecular sciences · 2025Review
- Cardiac Tissue Bioprinting: Integrating Structure and Functions Through Biomimetic Design, Bioinks, and Stimulation.Gels (Basel, Switzerland) · 2025Review
- Engineered heart tissue: Design considerations and the state of the art.Biophysics reviews · 2024Review
- Architecture design and advanced manufacturing of heart-on-a-chip: scaffolds, stimulation and sensors.Microsystems & nanoengineering · 2024Review
- An arrhythmogenic metabolite in atrial fibrillation.Journal of translational medicine · 2023Article
- High throughput screening system for engineered cardiac tissues.Frontiers in bioengineering and biotechnology · 2023Article
- Biotechnological advances and applications of human pluripotent stem cell-derived heart models.Frontiers in bioengineering and biotechnology · 2023Review
- Rianú: Multi-tissue tracking software for increased throughput of engineered cardiac tissue screening.Computer methods and programs in biomedicine update · 2023Article
- A Change of Heart: Human Cardiac Tissue Engineering as a Platform for Drug Development.Current cardiology reports · 2022Review
- PPARdelta activation induces metabolic and contractile maturation of human pluripotent stem cell-derived cardiomyocytes.Cell stem cell · 2022Article
- Progress in multicellular human cardiac organoids for clinical applications.Cell stem cell · 2022Review
- A micromachined force sensing apparatus and method for human engineered cardiac tissue and induced pluripotent stem cell characterization.Sensors and actuators. A, Physical · 2021Article
- Microphysiological System for High-Throughput Computer Vision Measurement of Microtissue Contraction.ACS sensors · 2021Article
- Human Pluripotent Stem Cells for Modeling of Anticancer Therapy-Induced Cardiotoxicity and Cardioprotective Drug Discovery.Frontiers in pharmacology · 2021Review
- Comparison of 10 Control hPSC Lines for Drug Screening in an Engineered Heart Tissue Format.Stem cell reports · 2020Article
- Engineered human myocardium with local release of angiogenic proteins improves vascularization and cardiac function in injured rat hearts.Biomaterials · 2020Article
- Use of Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes in Preclinical Cancer Drug Cardiotoxicity Testing: A Scientific Statement From the American Heart Association.Circulation research · 2019Review
- Engineering hiPSC cardiomyocyte in vitro model systems for functional and structural assessment.Progress in biophysics and molecular biology · 2019Review
- Biomimetic cardiovascular platforms for in vitro disease modeling and therapeutic validation.Biomaterials · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Cardiac tissue engineering describes techniques to constitute three dimensional force-generating engineered tissues. For the implementation of these procedures in basic research and preclinical drug development, it is important to develop protocols for automated generation and analysis under standardized conditions. Here, we present a technique to generate engineered heart tissue (EHT) from cardiomyocytes of different species (rat, mouse, human). The technique relies on the assembly of a fibrin-gel containing dissociated cardiomyocytes between elastic polydimethylsiloxane (PDMS) posts in a 24-well format. Three-dimensional, force-generating EHTs constitute within two weeks after casting. This procedure allows for the generation of several hundred EHTs per week and is technically limited only by the availability of cardiomyocytes (0.4-1.0 x 10
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.